Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Waldenstrom Macroglobulinemia 1Thrombocytopenia 1Sezary Syndrome 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Azacitidine 26venetoclax 12Peripheral Blood Stem Cell Transplantation 12fludarabine phosphate 10Mycophenolic Acid 9Whole-Body Irradiation 8Cyclosporine 8Cytarabine 7Cyclophosphamide 6Filgrastim 5Decitabine 5Busulfan 5Methotrexate 4fludarabine 3aldesleukin 3Tacrolimus 3Granulocyte Colony-Stimulating Factor 3Flow Cytometry 3Cytogenetic Analysis 3Cyclosporins 3Biopsy 3tipifarnib 2tagraxofusp 2ruxolitinib 2quizartinib 2eprenetapopt 2axatilimab 2X-Rays 2Transplantation 2Topotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Myelomonocytic, Chronic × Amplified Fragment Length Polymorphism Analysis × Clear all
NCT01165996 2019-03-04

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Case Comprehensive Cancer Center

Phase 1/2 Completed
25 enrolled 13 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Thrombocytopenia, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡